Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored Management After Induction Chemotherapy in Locally Advanced Rectal Cancer
2024-511609-44-00Phase 3Authorised
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Apr 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of irinotecan, capecitabine, oxaliplatin, folinic acid and fluorouracil in rectal cancer (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoints: R0 resection rate (Phase II) and 3-year disease-free survival (DFS) (Phase III). Planned start Apr 2024; status: authorised.
02
Drugs
irinotecancapecitabineoxaliplatinfolinic acidfluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-511609-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511609-44-00.